iX Biopharma Statistics
Total Valuation
iX Biopharma has a market cap or net worth of SGD 497.46 million. The enterprise value is 489.54 million.
Important Dates
The next estimated earnings date is Friday, February 5, 2027.
| Earnings Date | Feb 5, 2027 |
| Ex-Dividend Date | n/a |
Share Statistics
iX Biopharma has 1.09 billion shares outstanding. The number of shares has increased by 12.37% in one year.
| Current Share Class | 1.09B |
| Shares Outstanding | 1.09B |
| Shares Change (YoY) | +12.37% |
| Shares Change (QoQ) | +2.07% |
| Owned by Insiders (%) | 36.51% |
| Owned by Institutions (%) | 17.92% |
| Float | 662.15M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 62.49 |
| PB Ratio | 34.51 |
| P/TBV Ratio | 34.52 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio History Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 61.49 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 1.96, with a Debt / Equity ratio of 0.24.
| Current Ratio | 1.96 |
| Quick Ratio | 1.73 |
| Debt / Equity | 0.24 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -17.60 |
Financial Efficiency
Return on equity (ROE) is -115.98% and return on invested capital (ROIC) is -65.11%.
| Return on Equity (ROE) | -115.98% |
| Return on Assets (ROA) | -37.14% |
| Return on Invested Capital (ROIC) | -65.11% |
| Return on Capital Employed (ROCE) | -77.57% |
| Weighted Average Cost of Capital (WACC) | 9.71% |
| Revenue Per Employee | 215,162 |
| Profits Per Employee | -290,676 |
| Employee Count | 37 |
| Asset Turnover | 0.41 |
| Inventory Turnover | 4.02 |
Taxes
In the past 12 months, iX Biopharma has paid 8,000 in taxes.
| Income Tax | 8,000 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +250.00% in the last 52 weeks. The beta is 0.99, so iX Biopharma's price volatility has been similar to the market average.
| Beta (5Y) | 0.99 |
| 52-Week Price Change | +250.00% |
| 50-Day Moving Average | 0.52 |
| 200-Day Moving Average | 0.39 |
| Relative Strength Index (RSI) | 41.38 |
| Average Volume (20 Days) | 6,805,180 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, iX Biopharma had revenue of SGD 7.96 million and -10.76 million in losses. Loss per share was -0.01.
| Revenue | 7.96M |
| Gross Profit | 3.70M |
| Operating Income | -11.46M |
| Pretax Income | -10.75M |
| Net Income | -10.76M |
| EBITDA | -11.12M |
| EBIT | -11.46M |
| Loss Per Share | -0.01 |
Full Income Statement Balance Sheet
The company has 11.36 million in cash and 3.44 million in debt, with a net cash position of 7.92 million or 0.01 per share.
| Cash & Cash Equivalents | 11.36M |
| Total Debt | 3.44M |
| Net Cash | 7.92M |
| Net Cash Per Share | 0.01 |
| Equity (Book Value) | 14.41M |
| Book Value Per Share | 0.01 |
| Working Capital | 7.55M |
Full Balance Sheet Cash Flow
In the last 12 months, operating cash flow was -9.74 million and capital expenditures -187,000, giving a free cash flow of -9.93 million.
| Operating Cash Flow | -9.74M |
| Capital Expenditures | -187,000 |
| Depreciation & Amortization | 336,000 |
| Net Borrowing | -3.69M |
| Free Cash Flow | -9.93M |
| FCF Per Share | -0.01 |
Full Cash Flow Statement Margins
Gross margin is 46.48%, with operating and profit margins of -143.89% and -135.10%.
| Gross Margin | 46.48% |
| Operating Margin | -143.89% |
| Pretax Margin | -135.00% |
| Profit Margin | -135.10% |
| EBITDA Margin | -139.67% |
| EBIT Margin | -143.89% |
| FCF Margin | n/a |
Dividends & Yields
iX Biopharma does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -12.37% |
| Shareholder Yield | -12.37% |
| Earnings Yield | -2.38% |
| FCF Yield | -2.00% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
| Graham Formula Value | n/a |
| Graham Formula Upside | n/a |
Analyst Forecast
The average price target for iX Biopharma is 1.09, which is 138.46% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | 1.09 |
| Price Target Difference | 138.46% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 2 |
| Revenue Growth Forecast (3Y) | 205.21% |
| EPS Growth Forecast (3Y) | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 4 |